MyDosageBeta
Scan
Manifesto № 01 · Our Mission

Real talk —
why this market looks
the way it does.

No spin. Here's the reality.

§ I — The premise

Peptides aren't new and they aren't exotic. A lot of them already exist in nature — some are already in your body. And here's the thing that explains almost everything else: you generally can't patent a molecule that already exists in nature. No patent, no 20-year monopoly, no way to recover a billion dollars in trials. So the easy conclusion is "that's why pharma doesn't care."

But pharma isn't the enemy. Companies like Novo Nordisk and Eli Lilly are the ones actually funding the science — running the trials, doing the safety work, building the road the rest of us get to drive on. That deserves credit, not resentment.

§ II — The hard part

What they can patent is the hard part: engineering a more stable molecule, or solving delivery. Peptides fall apart easily, which is why getting one into a pill that survives your stomach and still works is a genuine feat. Rybelsus — oral semaglutide — is the live example: the molecule is engineered and protected, and the technology that lets you swallow it instead of injecting it is a separate, hard-won innovation. That's real R&D, and it costs real money.

So where's the friction? Cost and access. The price and the barriers climbed so high that, for a lot of people, access fell out of proportion to need. That's what fuels the anti-pharma feeling — and it bites hardest here, because some of these peptides have been used for years, and now the people who relied on them can't reach them.

That gap is where the gray market grows. People who want a piece of it, who feel entitled to it — because in their eyes it's not some brand-new invention, just a known compound. And that's where the tension sits: pharma on one side, compounding pharmacies in the middle, the open market on the other.

— we're not picking a side. just laying out the map.

§ III — How we handle evidence

We organize what's actually known, so you can make your own call.

There are three different kinds of evidence, and they are not the same thing.

  1. 01
    Clinical evidence

    Closed trials. Strict rules.

    Comes from closed clinical trials run under specific, consistent rules. Because the rules are so consistent, this evidence is straightforward to review and rate the same way every time. We've done that work — you'll see the ratings directly.

  2. 02
    Real-world evidence

    Messier. Shaped by context.

    Shaped by environment and conditions outside the clean boundaries of a trial. Still valuable, but harder to compare head-to-head.

  3. 03
    User experience

    Real people. Real stories.

    Real people telling you what happened to them. It matters — but you can't draw clinical conclusions from it, and we won't pretend you can.

Why does the distinction matter so much? Because clinical evidence exists for a specific reason. Regulators deciding how to spend public money need a very high, very specific bar before they'll fund something. That's a completely different question from asking a friend how something made them feel. Both are real. They just answer different things.

Here's what we add: we take user experience seriously enough to give it its own layer of evidence — clearly labeled as exactly what it is. Not dressed up as a trial. Just shown honestly, next to the clinical picture, so you can see both and decide for yourself how far to lean in or lean out. That decision is always yours.

§ IV — The human piece

And there's a human piece to this. It matters most when someone feels hopeless, or hits a strange side effect, and then finds another person who's been through the exact same thing. That connection can be powerful. So we connect you.

This is an ambitious thing to do well — and AI is what makes it possible to do it with real precision while keeping it simple enough to actually use.

in closing —

That's our purpose. That's what you're contributing to just by being here. Thank you for that — we hope you find it useful, and we're always open to feedback.

End of Vol. I